US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.88

+0.90173.34%

Post-market: 27.87-0.0134-0.05%16:10 EDT

Volume:1K

Turnover:34.96K

Market Cap:2.51M

PE:- -

High:28.22

Open:28.21

Low:27.86

Close:26.98

52wk High:28.62

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:2.13

T/O Rate:1.39%

Dividend:0.45

Dividend Rate:1.62%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Press Release: Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

PDS Biotech Reports Second Quarter 2026 Financial Results

CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial

From petri dish to patient:biotech’s formidable obstacle course

The West Australian

Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks

Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

NeuroThera Labs Wins Japanese Patent for Next-Generation Pain and Fever Therapy

Press Release: Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

Press Release: Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

Press Release: Theriva(TM) Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/NVIB/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.8834,"timestamp":1788379200000,"preClose":26.9817,"halted":0,"volume":1252,"hourTrading":{"tag":"盘后","latestPrice":27.87,"preClose":27.8834,"latestTime":"16:10 EDT","volume":6,"amount":167.3004,"timestamp":1788379804455,"change":-0.0134,"changeRate":-0.000481,"amplitude":0},"delay":0,"changeRate":0.033418946915872674,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Closed","change":0.9017,"latestTime":"09-02 16:00:00 EDT","open":28.209,"high":28.219,"low":27.86,"amount":34955,"amplitude":0.013305,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788422400000},"marketStatusCode":5,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":26.9817,"nav":27.01,"aum":2430909.13,"dividendRate":0.016206,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.87,"preClose":27.8834,"latestTime":"16:10 EDT","volume":6,"amount":167.3004,"timestamp":1788379804455,"change":-0.0134,"changeRate":-0.000481,"amplitude":0},"volumeRatio":2.130701},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.130701,"shares":90001,"dividePrice":0.45187,"high":28.219,"amplitude":0.013305,"preClose":26.9817,"low":27.86,"week52Low":24.54,"pbRate":"--","week52High":28.621,"institutionHeld":0,"latestPrice":27.8834,"eps":0,"divideRate":0.016206,"volume":1252,"delay":0,"ttmEps":0,"open":28.209,"prevYearClose":25,"prevWeekClose":27.0104,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":26.097,"twentyDayClose":27.7429},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659450421","title":"Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2659450421","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659450421?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345223/24675/en/fate-therapeutics-initiates-potentially-registrational-reclaim-ln-clinical-trial-of-ft819-for-the-treatment-of-lupus-nephritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","LABU","HYLG","BK4077","BMED","BK4230","GDOC","IDNA","CAR","MEDX","FATE","SLE","BK4139","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145865","title":"Press Release: Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145865","media":"Dow Jones","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145865?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"US$9.5 million as of June 30, 2026, increased from US$4.1 million as of. -- Cash and cash equivalents nearly doubled to US$3.65 million, up from. -- Total shareholders' equity increased to US$6.09 million, up approximately. 19% from US$5.10 million at December 31, 2025, reflecting a strengthened. -- Working capital improved significantly to approximately US$1.66 million. as of June 30, 2026, up from approximately US$0.42 million at December. 31, 2025, indicating strengthened short-term liquidity and full coverage. -- Quick ratio of 1.19 as of June 30, 2026, compared to 1.06 as of December. divided by current liabilities), confirming robust liquidity even on a. December 31, 2025. Importantly, approximately 47% of current liabilities,items, reflecting the Company's strong balance sheet management.Reduced Cash Burn and Cost Discipline-- Total operating expenses decreased by 53% in the second quarter of 2026. compared to the same period in 2025, to US$2.29 million from US$4.85. -- General ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","LU1244550577.SGD","BK4585","LCIZ","LU0795875169.SGD","LU0267386448.USD","QNTM","LU0390134368.USD","IAI","TM","BK4551","LU0106831901.USD","LU2023251221.USD","BK4581","IND","LCDL","LU2357305700.SGD","KBWB","LU0006306889.USD","BK4099","LU1732799900.SGD","BK4127","LU0210528500.USD","LU2133065610.SGD","LCID","NVIB","REZ","LU1791710400.SGD","LU1732800096.USD","LABU","LU2264538146.SGD","LU2089283258.USD","LU1791710582.SGD","LU0158827948.USD","LU2111349929.HKD","03160","LU1244550221.USD","LU0098860793.USD","LU1548497426.USD","EQR","LU0106261372.USD","VMRK","LU1988902786.USD","LU1989772923.USD","LU0234570918.USD","LU0912757837.SGD","BK4596","LU1244550494.USD","IE00B775SV38.USD","BK4516","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659195237","title":"Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2659195237","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659195237?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:02","pubTimestamp":1786654920,"startTime":"0","endTime":"0","summary":"Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regenerationContinued favorable safety and tolerab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3345007/0/en/satellos-reports-second-quarter-2026-financial-results-and-highlights-company-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","LU2065732104.USD","BMED","IDNA","PRGS","IND","BK4139","MSLE","GDOC","NVIB","MEDX","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659627661","title":"CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659627661","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659627661?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344920/0/en/camp4-reports-second-quarter-2026-financial-results-and-corporate-highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","HYLG","NVIB","GDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162993","title":"Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162993?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"-- Achieved Q2 2026 PEMGARDA  net product revenue of $14.3. million, representing 21% growth versus Q2 2025 net product revenue of. -- Completed rapid enrollment in VYD2311 DECLARATION clinical trial. expansion cohort and LIBERTY clinical trial, driven by strong subject. -- DECLARATION pivotal clinical trial enrollment is complete; the ongoing. study is approaching its planned analysis, and in lieu of a Q2 2026. quarterly earnings call, Invivyd plans to hold an investor call post. -- Strong balance sheet with Q2 2026 ending cash and cash equivalents of. $160.1 million anticipated to provide runway through DECLARATION pivotal. data readout and support potential commercial launch readiness for. 30, 2026, compared to $11.8 million in for the quarter ended June 30,-- In July 2026, Invivyd announced receipt of twelve months' advanced notice. of emergency use authorization  termination for PEMGARDA and that. the company is in dialogue with the U.S. Food and Drug Administration.  about approp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IDNA","HYLG","BK4232","BNTX","BK4535","BK4585","R","BK4022","BK4139","BK4551","BK4539","BK4548","IND","BK4588","BK4568","MEDX","NVIB","IVVD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","NVIB","IDNA","HYLG","TBXU","BK4588","BK4585","BK4230","FBT","BK4539","GNOM","MEDX","SYNB","CR","CRBU","CAR","ORR","LD","CNCR","BK4161","BK4022","BK4195","PFS","GDOC","BK4139","IBB","BK4211","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152369","title":"PDS Biotech Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152369","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152369?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624200,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Aug.  13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344498/37149/en/pds-biotech-reports-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","NVIB","ORR","BK4588","BK4585","MEDX","PFS","GDOC","PDS","BK4092","BK4211","BK4581","IDNA","HYLG","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659613658","title":"CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659613658","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659613658?lang=en_us&edition=fundamental","pubTime":"2026-08-13 14:12","pubTimestamp":1786601532,"startTime":"0","endTime":"0","summary":"Amur Minerals ( ($GB:CRTX) ) has shared an announcement. CRISM Therapeutics has completed the Site Initiation Visit at its lead NHS clinical trial ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crism-therapeutics-clears-key-step-to-begin-phase-ii-glioblastoma-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crism-therapeutics-clears-key-step-to-begin-phase-ii-glioblastoma-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","MEDX","IDNA","BK4007","NVIB","GDOC","BK4539","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659131647","title":"From petri dish to patient:biotech’s formidable obstacle course","url":"https://stock-news.laohu8.com/highlight/detail?id=2659131647","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659131647?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:12","pubTimestamp":1786576331,"startTime":"0","endTime":"0","summary":"A biotech breakthrough can be worth billions – if it survives the journey. Bulls N’ Bears follows the trek from a promising discovery through to a product doctors can actually use.","market":"nz","thumbnail":"https://images.thewest.com.au/publication/C-22720423/37f3ab3f7c773a9a699efc346c96f6d2e782abe6.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22720423/37f3ab3f7c773a9a699efc346c96f6d2e782abe6.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/from-petri-dish-to-patientbiotechs-formidable-obstacle-course-c-22720423","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/from-petri-dish-to-patientbiotechs-formidable-obstacle-course-c-22720423","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["EES","XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659926188","title":"Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2659926188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659926188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:37","pubTimestamp":1786567029,"startTime":"0","endTime":"0","summary":"The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 2026, Outlook Therapeutics announced U.S. FDA approval of LYTENAVA (bev...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","BMED","MEDI","LENZ","FRTY","PINK","BK4139","TBXU","MRNX","BK4585","GNMX","LABU","MRNY","IDNA","IEIH","PSCH","BK4007","GDOC","XLVX","IYH","BBP","RSPH","BK4588","IBB","BK4539","TECB","SYNB","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907259","title":"Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907259?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"-- On track for September 2026 top-line results from Phase 2b clinical trial.  evaluating laromestrocel as a potential adjunct treatment for. hypoplastic left heart syndrome , a rare pediatric disease and. -- Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE. Healthspan competition based on published clinical trial results which. indicated laromestrocel increased 6-minute walk distance in patients with. -- Three new independent Directors join Longeveron's Board of Directors. laromestrocel as a potential adjunct therapy for HLHS are anticipated in. -- In May, the Company announced that the U.S. Food and Drug Administration.  held a Type C meeting in late March 2026 focused on the ELPIS II. Phase 2b clinical trial and upcoming data readout.-- Also in May, the Company announced that the independent Data Monitoring. Committee  completed its final prespecified data review for ELPIS II. Phase 2b clinical trial . The DMC performed a risk-benefit. assessment, indicated n","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4232","LGVN","EMA","MEDX","AD","GDOC","IDNA","NVIB","DMC","R","BK4022","HYLG","BK4189","BK4081","BK4132","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658700929","title":"NeuroThera Labs Wins Japanese Patent for Next-Generation Pain and Fever Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2658700929","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658700929?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:08","pubTimestamp":1786540125,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an update. NeuroThera Labs Inc., a clinical-stage biotech and majority-owned subsidiary of SciSparc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-wins-japanese-patent-for-next-generation-pain-and-fever-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-wins-japanese-patent-for-next-generation-pain-and-fever-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972189","title":"Press Release: Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972189","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972189?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536000,"startTime":"0","endTime":"0","summary":"double-blind, placebo-controlled global trial evaluating two doses of. AP01 dosed twice daily in patients with progressive pulmonary fibrosis. . This 52-week trial is designed to assess safety and efficacy of. AP01, with a primary endpoint of change in lung function measured by. forced vital capacity . The study overenrolled beyond its target. enrollment of 375, with a total of 398 patients randomized into three. treatment cohorts. Topline data are anticipated in the second half of. -- In September 2026, the Company plans to present two abstracts at the ERS. Congress in Barcelona, Spain. The first poster will highlight data. modeling effective AP01 distribution throughout the target tissue in both. healthy and idiopathic pulmonary fibrosis  lungs. The second poster. will describe the integration of patient perspectives into clinical trial. design. Detailed poster session information will be provided in advance","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN","MEDX","HYLG","NVIB","FVC","GDOC","BK4007","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658089139","title":"Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658089139","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658089139?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536000,"startTime":"0","endTime":"0","summary":"Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Socie","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343572/0/en/avalyn-reports-second-quarter-2026-financial-results-and-recent-business-highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","IDNA","HYLG","MEDX","FVC","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658390895","title":"Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658390895","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658390895?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:30","pubTimestamp":1786534200,"startTime":"0","endTime":"0","summary":"Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343555/14025/en/arbutus-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","HYLG","GDOC","MEDX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658451129","title":"Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451129","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451129?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481580,"startTime":"0","endTime":"0","summary":"and the OLE  trial to assess the totality of. available efficacy and safety data and to support an informed. determination of next steps for the ARD-101 program. In June 2026, the. Company terminated the HERO and the OLE trial and does not currently. intend to resume these trials as previously designed.-- In May 2026, the Company announced that the U.S. Food and Drug. Administration  placed a full clinical hold on its investigational. new drug application  for ARD-101, related to the Company's. previously announced voluntary pause. The clinical hold applies to all. previously ongoing clinical studies under the IND, including the Phase 3. HERO trial evaluating ARD-101 for the treatment of hyperphagia in. patients with Prader-Willi Syndrome  and the Phase 3 OLE trial.Second Quarter 2026 Financial Highlights-- Cash Position: As of June 30, 2026, Aardvark had cash, cash equivalents. and short-term investments of $73.9 million, compared to $91.2 million as. of March 31, 2026. Based on curre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","NVIB","MEDX","GDOC","BK4007","IND","BMED","HYLG","AARD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658194913","title":"Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition","url":"https://stock-news.laohu8.com/highlight/detail?id=2658194913","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658194913?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:05","pubTimestamp":1786453500,"startTime":"0","endTime":"0","summary":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342811/0/en/longeveron-named-a-finalist-team-and-will-receive-a-1-000-000-milestone-2-award-for-the-xprize-healthspan-global-competition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","HYLG","LGVN","TISI","BK4139","IDNA","MSC","GDOC","NVIB","AD","BK4120","MEDX","BK4150","BK4575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658099084","title":"Press Release: Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658099084","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658099084?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:01","pubTimestamp":1786449660,"startTime":"0","endTime":"0","summary":"reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment. -- New manufacturing batch completed including process enhancements that. have further reduced already low levels of process impurities.-- Kalaris is currently conducting a Phase 1b/2, multi-ascending dose,The study aims to assess the safety and efficacy of repeat doses of TH103. at different dose levels and to identify the optimal dose and regimen for. potential Phase 3 development. Preliminary data from the Phase 1b/2 study. is expected in the first half of 2027.-- As previously announced, Kalaris expanded its leadership team with the. hire of Liisa Bayko as Chief Financial Officer. Ms. Bayko brings more. than two decades of experience in biotechnology finance, strategy, and. capital markets, most recently serving as Managing Director and Senior. Biotechnology Analyst at Evercore ISI, where she was consistently. recognized as one of the industry's top-ranked analysts covering small-. -- As announced recently, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","NVIB","BK4139","GDOC","IDNA","BMED","KLRS","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990407","title":"IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990407","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990407?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Pha","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342668/0/en/imunon-reports-second-quarter-2026-financial-results-and-provides-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GDOC","IDNA","IMNN","NVIB","HYLG","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990336","title":"Press Release: Theriva(TM) Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990336?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"Phase 2a clinical trial entitled \"A Phase IIa, single-arm, single-center,-- The VIRAGE2 study design incorporates feedback from both the. European Medicines Agency  and the U.S. Food and Drug. VIRAGE Phase 2b trial in metastatic PDAC patients treated with 2. repeated dosing of VCN-01 may provide additional clinical benefit.-- The VIRAGE2 trial will evaluate the safety and feasibility of. administering at least 3 doses of VCN-01 given approximately 2. The trial is expected to enroll 6 evaluable patients. Results from. the VIRAGE2 study will inform the VCN-01 dosing regimen for","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","LU0053666078.USD","BK4107","BK4555","EMA","LU0210528500.USD","HYLG","GDOC","TM","03160","L","BK4588","BK4604","BK4081","LU2487616109.SGD","BK4099","IDNA","BK4585","TOVX","MEDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":4,"totalSize":144,"code":"91000000","status":"200"}]}}